Assessment of Hospitalizations in Patients with Generalized Myasthenia Gravis (gMG) Before and During Treatment with Ravulizumab: Results from a Global Registry (P1-11.016)
To assess rates and characteristics of hospitalizations among patients with anti-acetylcholine receptor antibody-positive (AChR-Ab+) gMG before and during ravulizumab treatment in clinical practice (MG SPOTLIGHT Registry; NCT04202341).
Authors
- Michael Nicolle
- Gary Cutter (ORCID: https://orcid.org/0000-0002-8455-980X)
- Samir Macwan
- Lida Zeinali
- James Winkley
- Rup Tandan
- Christopher A. Scheiner
- Chuang LIU (ORCID: https://orcid.org/0000-0002-2445-0845)
- Michael Pulley (ORCID: https://orcid.org/0000-0003-1879-725X)
- Ali A. Habib (ORCID: https://orcid.org/0000-0003-3432-9747)
Institutions
- University of California, Irvine (US)
- London Health Sciences Centre (CA)
- University of Vermont Medical Center (US)
- University of Tennessee Medical Center (US)
- University of Alabama at Birmingham (US)
- University of Florida (US)
- AstraZeneca (Brazil) (BR)
- Alexion Pharma (Switzerland) (CH)
- University of Tennessee at Knoxville (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208772
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00